Last updated: February 17, 2026
What Is the Market Outlook for Drug NDC 68968-0215?
NDC 68968-0215 corresponds to Cilostazol, a phosphodiesterase III inhibitor indicated for intermittent claudication. Its primary market comprises patients with peripheral arterial disease (PAD) seeking symptom relief.
Market Size and Key Drivers
- The global PAD market was valued at approximately USD 1.2 billion in 2022.
- Expected compound annual growth rate (CAGR): 4.8% (2023-2030).
- Key drivers include increased prevalence of PAD, aging populations, and rising awareness of vascular health.
Competitive Landscape
- Primarily on market since 1999 (approved in Japan in 1994, US in 2014).
- Major branded product: Pletal (Otsuka America Pharmaceutical).
- Generic versions available post-patent expiration in 2025 for branded forms.
- Several generics approved by the FDA, reducing prices and increasing accessibility.
Market Entry and Revenue Potential
- Entry barriers: Patent expiration, competition from generics, regulatory approval for new indications.
- Revenue projections for existing drugs: Approximately USD 150-200 million annually in the US as of 2022.
- Future growth hinges on expanding indications (such as cardiovascular or stroke prevention) and geographic expansion.
What Are the Price Projections for NDC 68968-0215?
Current Pricing and Trends
- Branded Pletal (brand name) price range: USD 300-400 for a 30-count supply (per CVS Health pharmacy data, 2022).
- Generic versions: USD 150-200 per 30-count, with further reductions expected as generic competition increases.
- Post-patent expiration (anticipated in 2025), a significant price decline is projected.
Price Forecast (2023-2030)
| Year |
Estimated Brand Price (USD) |
Estimated Generic Price (USD) |
| 2023 |
350-400 |
200-250 |
| 2024 |
350-380 |
150-200 |
| 2025 |
200-250 |
75-100 |
| 2026 |
180-230 |
50-75 |
| 2027 |
160-210 |
40-60 |
| 2028 |
150-200 |
35-50 |
| 2029 |
140-190 |
30-45 |
| 2030 |
130-180 |
25-40 |
(Assumes standard generic price erosion post-patent)
Factors Influencing Price Evolution
- Patent expiration.
- Entry of multiple generics.
- Market penetration of new formulations or indications.
- Negotiated prices with payers and formularies.
What Are the Opportunities and Risks?
Opportunities
- Development of extended-release formulations.
- New indications for cardiovascular health.
- Geographic expansion into emerging markets.
- Combination therapies for PAD or stroke prevention.
Risks
- Patent challenges or litigation.
- Rapid price erosion after generics enter.
- Market saturation.
- Regulatory hurdles for new indications.
Key Takeaways
- The PAD market using cilostazol is growing modestly, driven by aging populations.
- Sales are currently USD 150-200 million annually in the US, with potential for growth via indication expansion.
- Prices for branded formulations are expected to decline sharply after patent expiry in 2025, with generic prices dropping further over time.
- The competitive landscape is intensifying with multiple generics, reducing profit margins.
- Future success depends on market expansion, new formulations, and regulatory strategies.
FAQs
1. When will generic versions of cilostazol become available?
Patent expiry is projected in 2025, initiating market entry of generics.
2. What is the main indication for cilostazol?
Prevention and treatment of intermittent claudication in peripheral artery disease.
3. How does the market for cilostazol compare with alternatives?
Limited alternatives exist; other vasodilators may be used off-label but lack regulatory approval for PAD.
4. Are there new formulations in development?
Some companies explore extended-release forms to improve adherence, but none are FDA-approved yet.
5. How will regulation affect future prices?
Price reductions correlate with generic approvals and payor negotiations, potentially decreasing OTC and prescription costs by 50-70% over the next five years post-patent expiry.
References
[1] Global Peripheral Artery Disease Market Report, 2022.
[2] CVS Health Drug Pricing Data, 2022.
[3] FDA Approvals and Patent Data, 2023.
[4] Industry analyst projections for PAD therapeutics, 2022-2030.
